Press Releases

Mar 08, 2013

Veracyte Announces UnitedHealthcare Coverage Policy For the Afirma® Gene Expression Classifier

Read More

Feb 15, 2013

New Article in PLOS Currents: Evidence on Genomic Tests Supports Use of Veracyte's Afirma® Gene Expression Classifier to Resolve Ambiguous Thyroid Nodule Biopsies

Read More

Jan 07, 2013

Veracyte Announces That New Guidelines Include Molecular Testing for Indeterminate Thyroid Nodules To Reduce Unnecessary Surgeries

Read More

Oct 22, 2012

Veracyte Announces Publication of Analytical Validity Study for its Afirma® Gene Expression Classifier

Read More

Aug 29, 2012

Veracyte Receives New York State License for Afirma® Gene Expression Classifier

Read More

Jul 17, 2012

New Study Suggests That Use of Veracyte’s Afirma® Gene Expression Classifier Helps to Significantly Reduce Surgeries in Patients with Ambiguous Thyroid Nodule Cytology Results

Read More

Jun 25, 2012

Veracyte Announces Study Results Published Online in New England Journal of Medicine Which Suggest that Its Afirma® Gene Expression Classifier Can Reduce Unnecessary Thyroid Surgeries

Read More

Apr 16, 2012

Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis

Read More

Apr 05, 2012

Richard T. Kloos, MD, Joins Veracyte as Senior Medical Director

Read More

Jan 20, 2012

Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients

Read More